
Allarity Therapeutics (NASDAQ: ALLR) has confirmed expanded eligibility for its ongoing Phase 2 stenoparib trial in advanced ovarian cancer, opening the study to patients with primary platinum-refractory disease and patients whose disease can be evaluated clinically but is not measurable under standard Response Evaluation Criteria in Solid Tumors (RECIST). The study was previously enrolling only patients with advanced platinum-resistant or platinum-ineligible ovarian cancer.
According to Allarity, the expansion was prompted by clinical investigators’ enthusiasm for stenoparib as a well-tolerated, oral treatment for advanced ovarian cancer patients and reflects the encouraging early performance of the trial in platinum-resistant and platinum-ineligible patients. The addition of these new patients now allows Allarity to build on prior evidence of durable clinical benefit in primary platinum-refractory disease while evaluating stenoparib across a broader spectrum of advanced ovarian cancer patients.
Kathleen N. Moore, MD, MS, principal investigator of the Phase 2 stenoparib trial, deputy director and director of Phase 1 oncology trials at the Fred & Pamela Buffett Cancer Center, and professor in the department of obstetrics and gynecology at the University of Nebraska Medical Center, commented, “We are excited about the expansion of eligibility to include patients with primary platinum-refractory disease as well as those with resistant but not measurable disease, allowing access to a potentially effective therapeutic agent among patients routinely excluded from clinical trial participation. We are hopeful that these patients will benefit from stenoparib and that we can learn more about best treatment options for all patients with ovarian cancer.”
In a statement, Thomas Jensen, CEO of Allarity, remarked, “We’re encouraged by the progress we’ve seen in the trial, and we’re excited to build on it. The strategic expansion of patient eligibility in this trial allows us to efficiently map the potential of stenoparib across multiple high-unmet-need populations. A strong result in any one of the three groups could support further development. And if the data support development in more than one group, stenoparib could ultimately reach more patients and address a larger market.”
The Phase 2 study builds on findings from earlier experience in the trial in heavily pretreated patients with advanced, recurrent ovarian cancer, presented at the ESMO Gynaecological Cancers Congress in June 2026:
- Treatment duration and survival: In a patient with primary platinum-refractory disease, treatment duration was nearly one year with survival exceeding two years.
- Clinical benefit: Extended clinical benefit in platinum-resistant ovarian cancer patients with BRCA-mutant and BRCA-wild-type disease, with some patients staying on drug nearly 2.5 years.
- Complete, confirmed response: An unprecedented response in a heavily pretreated platinum-resistant patient retreated with a PARP inhibitor.
- Median overall survival: A median overall survival of 22 months in patients treated with stenoparib, compared with approximately 16 months for recently FDA-approved drugs in similar patients.






